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ing supported by other studies (4,5). As wall stress also is increased
in advanced cardiomyopathy, the association between LGE and
wall stress referred to by the authors is not surprising, because
LGE also is a feature of advanced cardiomyopathy (4,5).
One would expect that if increased wall stress is the underlying
mechanism of myocardial contrast enhancement, it is likely to be
diffuse rather than the focal process observed with LGE. Diffuse
contrast enhancement cannot be detected with the technique of
LGE, because this method requires the presence of apparently
normal adjacent myocardium without contrast enhancement.
However, because shortened post-contrast myocardial T1 times
have been shown to correlate with histological fibrosis (6) in
patients with cardiomyopathy, wall stress as the underlying mech-
anism of contrast enhancement seems unlikely. Interestingly,
recent research in hypertensive patients revealed an absence of
LGE despite increased wall stress compared with controls (7).
To determine conclusively that wall stress contributes to the
presence of LGE in nonischemic cardiomyopathy independently
of regional fibrosis would require contemporaneous measurement
of LGE and wall stress coupled with histological examination of
areas of myocardium in which LGE is present. To our knowledge,
this has not been performed, and given the lack of invasive pressure
measurement along with the unavailability of histological samples,
such analysis is not possible from our study population.
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Dynamic Left Ventricular
Outflow Tract Obstruction
and Acute Heart Failure in
Tako-Tsubo Cardiomyopathy
Given the relative paucity of data regarding tako-tsubo cardiomy-
opathy (TC) and the risk of heart failure, Madhavan et al. (1) are
to be commended for their work recently published in the Journal.
However, we wish to raise one issue not mentioned in their
paper. It is recognized that TC can be complicated by reversible
systolic anterior motion (SAM) of the mitral valve (MV) with
dynamic left ventricular outflow tract obstruction (LVOTO) (2).
This can be associated with significant mitral regurgitation (MR).
The pathophysiological basis of this complication remains un-
known. Two studies, both including more than 100 patients, each
reported an incidence of SAM and LVOTO in more than 10% of
TC cases (3,4). Thus, dynamic LVOTO is certainly not a rare
phenomenon in association with TC.
Hypotension may develop in patients with TC first due to left
ventricular systolic dysfunction, second due to significant MR
secondary to SAM of the MV, third due to dynamic LVOTO, or
fourth a combination of these factors (5). Alternatively, hypoten-
sive patients presenting with chest pain and ischemic electrocar-
diographic changes may, of course, have cardiogenic shock due to
acute coronary syndrome. It is clinically important to differentiate
the cause of hypotension in such patients because the immediate
management varies depending on the underlying etiology.
In patients with acute coronary syndrome, intra-aortic balloon
pump (IABP) counterpulsation improves coronary perfusion (dur-
ing diastolic balloon inflation) and reduces systemic afterload
(during systolic balloon deflation). The use of positive inotropes
can also improve the hemodynamic status. In the patient with
suspected TC who is hypotensive, these same therapies can be used
if there is no SAM with LVOTO. By contrast, if there is
significant LVOTO, both IABP placement and inotropes are
relatively contraindicated because they would worsen the dynamic
gradient and thereby further jeopardize cardiac function (6).
Therefore, patients with predominant pump failure can safely
receive IABP counterpulsation and inotropes, whereas those with
significant LVOTO should instead be managed more conserva-
tively with cautious fluids (if no pulmonary edema) and beta-
blockers (to increase diastolic filling time and thus end-diastolic
volume) (7).
We congratulate the authors on their retrospectively developed
and prospectively validated risk scoring system. However, we
believe that their final sentence “the use of intra-aortic balloon
pump counterpulsation may be the preferred treatment strategy for
moderate or severe hemodynamic compromise” would be further
enhanced by the addition of the important clinical caveat “assum-
ing there is no echocardiographic evidence of LVOTO.” We
wonder whether the authors encountered cases of LVOTO in their
series, and, if so, what percentage of these patients had acute heart
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described in their paper?
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Reply
We thank Drs. Shah and Curzen for their interest in our recent
paper (1). Among the 118 patients in our study, 92 underwent left
ventriculography, and mitral regurgitation (MR) was quantified as
grade 1, 2, 3, and 4 in 27%, 16%, 9%, and 5%, respectively. Grade
3 or 4 MR was associated with lower left ventricular ejection
fraction (median 35% [interquartile range: 22% to 44%] vs. 45%
[interquartile range: 33% to 51%], p  0.02), higher incidence of
left ventricular outflow tract (LVOT) obstruction (36% vs. 7%,p 0.02), and heart failure (HF) (62% vs. 39%, p 0.08). Twelve
f the 13 patients with grade 3 or 4 MR underwent echocardiog-
aphy, which identified LVOT obstruction and systolic anterior
otion of the anterior mitral leaflet (n  4), tethering of the
nterior mitral leaflet (n 5), and degenerative mitral valve disease
(n  3) as the potential mechanisms for valve dysfunction.
Follow-up echocardiography demonstrated complete resolution of
MR in 54% and mild residual MR in the remaining patients.
LVOT obstruction was detected by echocardiography in 10%.
The occurrence of LVOT obstruction was not significantly differ-
ent among patients with and without HF (8% vs. 13%, p  0.5).
The 4 patients with HF who also had LVOT obstruction all
demonstrated grade 3 or 4 MR, and cardiogenic shock developed
in 2 patients. An intra-aortic balloon pump was not used in these
patients. All 4 had complete resolution of HF at the time of
discharge, and a follow-up echocardiogram showed resolution of
LVOT obstruction and normalization of left ventricular systolic
function.
Thus, we agree with Drs. Shah and Curzen that significant MR
may be present and appears to be more prevalent in patients with
HF, but it is reversible. LVOT obstruction was noted in 10% of
the cohort and when present in patients with HF, coexisted with
grade 3 or 4MR.We recommend that patients with apical ballooning
syndrome and severe HF and/or hypotension undergo echocardiog-
raphy to detect LVOT obstruction because its presence should modify
management. These patients are best treated with careful fluid
management to avoid excessive preload reduction, beta-blockers (if
tolerated), and occasionally peripheral vasoconstrictors.
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